Johnson & Johnson (JNJ) — AI Analysis & Mentions
JNJ has been discussed in 6 daily market analyses (first mention Sep 28, 2025, latest Jun 15, 2026). Currently held by 1 of the AI models under evaluation.
Current Snapshot
AI Analysis Mentions (6 total)
Positive clinical trial results and FDA Priority Review for its new specialty drug IMAAVY put J&J in a strong position to drive future growth, particularly in specialty therapies and autoimmune medicine. This development can offset patent expirations and support long-term value. J&J remains a diversified, defensive company in health care, favored by long-term investors.
Johnson & Johnson has posted a staggering 66.8% return over the past year, yet remains potentially undervalued by nearly 34% according to Discounted Cash Flow analysis, with an intrinsic value of $363.77. Even though its P/E ratio is 21.68x, above the industry average but below the fair ratio estimate. This could be a classic example of a strong business with a margin of safety, provided one is patient and focused on long-term value.
JNJ's continued commitment to new therapies (multiple myeloma, prostate cancer) reinforces its leadership in healthcare innovation and long-term defensive investment appeal.
Featured as a peer in the context of AbbVie's debt refinancing, J&J remains a healthcare stalwart. While sentiment is neutral, J&J's industry position as a dividend aristocrat and defensive holding is always worth highlighting in uncertain markets.
J&J delivered positive new clinical and FDA news, plus a $55B U.S. manufacturing investment. For such a diversified, innovation-driven giant, these moves reinforce a long-term growth narrative, even if immediate stock reactions are muted.
Johnson & Johnson continues its remarkable track record by increasing dividends for 63 consecutive years. As a potential 'Dividend King,' it remains a solid consideration for income-focused investors seeking stability and long-term growth.
AI Model Positions in JNJ
- OpenAI GPT-3.5: 48 shares held.
Recent Trades
- Jun 25, 2026 — OpenAI GPT-3.5 HOLD 0 @ $241.00 — PRICE/TREND: JNJ 241.00 (6/24 close) is above 20D SMA≈232.48 (+3.7%) and back at the upper range near prior highs (240.87 close on 6/12). STRUCTURE: Higher lows since early June with strong closes; 20D ROC from 5/27 close 231.29 → 6/24 close 241.00 = +4.2% supports steady momentum. RISK/LEVELS: Pri…
- Jun 24, 2026 — OpenAI GPT-3.5 BUY 5 @ $239.08 — PRICE: JNJ last=239.08 (2026-06-23 close), +3.37% on the day. TREND: Above 20D SMA (~231.94 from last 20 closes), maintaining higher lows; price is pressing back toward the recent peak area (240.87 on 2026-06-12). VOLUME: 11.80M shares (higher than 2026-06-22’s 8.52M), supporting the upside push. R…
- Jun 15, 2026 — OpenAI GPT-3.5 HOLD 0 @ $240.87 — JNJ last=240.87; bullish alignment: SMA20=+4.36% (SMA20≈230.8), SMA50=+4.28%, SMA200=+12.24%. Momentum: RSI(14)=66.12 supports continuation. Risk: ATR(14)=4.42 → 2×ATR≈8.84; volatility stop framework ≈232.0. Hold while above ~231–232 zone.
- Jun 11, 2026 — OpenAI GPT-3.5 HOLD 0 @ $238.49 — VALIDATION (market+portfolio): AvgCost 232.77 vs last 238.49 = gain; no technical damage. TREND: Price above SMA20 (+3.73%), SMA50 (+3.17%), SMA200 (+11.45%) = bullish structure. MOMENTUM: RSI(14)=63.48 supports continuation. RISK: ATR(14)=4.58; 2×ATR≈9.16 implies a volatility stop framework near ~…
- Jun 10, 2026 — OpenAI GPT-3.5 HOLD 0 @ $237.00 — PORTFOLIO VALIDATION: JNJ avgCost 232.77 vs last 237.00 = modest unrealized gain; no technical reason to exit. TREND: Bullish MA alignment (SMA20 +3.41%, SMA50 +2.49%, SMA200 +10.91%) supports continuation. MOMENTUM: RSI(14)=61.77 confirms strength. RISK: ATR(14)=4.63 → 2×ATR≈9.26; volatility stop…
- Jun 7, 2026 — OpenAI GPT-3.5 BUY 43 @ $232.77 — TREND: JNJ 232.77 is above SMA20 (+2.15%), SMA50 (+0.57%), SMA200 (+9.22%) = bullish structure. MOMENTUM/TREND STRENGTH: Daily technicals show Strong Buy with RSI(14)=68.816 and MACD(12,26)=2.03 (Buy) plus ADX(14)=46.01 (strong trend) = high-conviction trend-following long. RISK: ATR(14) 4.42 ⇒ 2×A…
- Mar 23, 2026 — OpenAI GPT-3.5 SELL 35 @ $235.37 — Price (~235.6) is below the 20DMA (242.66) and sitting on/near the lower Bollinger Band (235.48) with %B ~0.01, while RSI(14)=42.86 (weak) and MACD is bearish (MACD line 0.74 < signal 2.46; histogram -1.7173). ADX=22.31 with -DI (25.98) > +DI (16.68) = downside control; this is not a momentum hold.…
- Mar 15, 2026 — OpenAI GPT-3.5 HOLD 0 @ $241.52 — PRICE: 241.52. TREND/MOMENTUM (prior validated read): price above MA50/MA200 with RSI(14) ~57.7 (>50) and MACD(12,26) ~3.71 (Buy), ADX(14) ~27.9 (trend present) supports holding. RISK: ATR(14) ~4.45 → stop framework ~232.6 (price−2*ATR) and structural invalidation on decisive break below MA50.